Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8642802rdf:typepubmed:Citationlld:pubmed
pubmed-article:8642802lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:8642802lifeskim:mentionsumls-concept:C0149721lld:lifeskim
pubmed-article:8642802lifeskim:mentionsumls-concept:C0455825lld:lifeskim
pubmed-article:8642802lifeskim:mentionsumls-concept:C0301630lld:lifeskim
pubmed-article:8642802lifeskim:mentionsumls-concept:C0140591lld:lifeskim
pubmed-article:8642802pubmed:dateCreated1996-7-12lld:pubmed
pubmed-article:8642802pubmed:abstractTextIt is generally accepted that the development of left ventricular hypertrophy (LVH) represents a multifactorial phenomenon that also involves neurohormonal mechanisms. This finding may account for the ability of angiotensin-converting enzyme inhibitors to induce faster and more complete reversal of LVH than that observed with other antihypertensive treatments. The sympathetic system is also involved in the genesis of hypertension-induced LVH. We assessed the effects of satisfactory long-term treatment with rilmenidine, a new oxazoline with a potent antihypertensive action, on cardiovascular structural abnormalities and cardiac endocrine function in hypertensive patients with left ventricular hypertrophy. Eleven patients underwent M-mode and two-dimensional Doppler echocardiography, peripheral pulsed Doppler flowmetry, determination of plasma atrial natriuretic factor [(ANF) pg/ml] and renin activity, and 24-h urine electrolyte excretion under control conditions, after 4 weeks of blood pressure normalization, after 1 year of satisfactory antihypertensive treatment and, finally, 4 weeks after therapy withdrawal. I.VH (g/m2 body surface area) was reversed after 1-year treatment (from 152 +/- 5 to 131 +/- 4, p < 0.05). One-year treatment induced an improvement in brachial artery compliance (cm4/dyne.10(7)) (from 0.92 +/- 0.06 to 1.16 +/- 0.08, p < 0.05) that persisted after withdrawal of treatment (1.17 +/- 0.06, p < 0.05). Plasma renin activity and urinary electrolyte excretion did not change throughout the study, whereas ANF remained unchanged after blood pressure normalization (48.4 +/- 6.2 versus 44.7 +/- 2.9, NS), fell after reversal of LVH (28.6 +/- 3.4, p < 0.05), and remained significantly lower than under control conditions after therapy withdrawal (27.5 +/- 2.9, p < 0.05). These results demonstrate that a satisfactory long-term antihypertensive treatment with rilmenidine is able to reverse cardiovascular structural changes and to restore cardiac endocrine function.lld:pubmed
pubmed-article:8642802pubmed:languageenglld:pubmed
pubmed-article:8642802pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8642802pubmed:citationSubsetIMlld:pubmed
pubmed-article:8642802pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8642802pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8642802pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8642802pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8642802pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8642802pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8642802pubmed:statusMEDLINElld:pubmed
pubmed-article:8642802pubmed:issn0160-2446lld:pubmed
pubmed-article:8642802pubmed:authorpubmed-author:TrimarcoBBlld:pubmed
pubmed-article:8642802pubmed:authorpubmed-author:VolpiIIlld:pubmed
pubmed-article:8642802pubmed:authorpubmed-author:RussoRRlld:pubmed
pubmed-article:8642802pubmed:authorpubmed-author:IovinoGGlld:pubmed
pubmed-article:8642802pubmed:authorpubmed-author:De LucaNNlld:pubmed
pubmed-article:8642802pubmed:authorpubmed-author:MoriscoCClld:pubmed
pubmed-article:8642802pubmed:authorpubmed-author:ArgenzianoLLlld:pubmed
pubmed-article:8642802pubmed:authorpubmed-author:SarnoDDlld:pubmed
pubmed-article:8642802pubmed:issnTypePrintlld:pubmed
pubmed-article:8642802pubmed:volume26 Suppl 2lld:pubmed
pubmed-article:8642802pubmed:ownerNLMlld:pubmed
pubmed-article:8642802pubmed:authorsCompleteYlld:pubmed
pubmed-article:8642802pubmed:paginationS29-33lld:pubmed
pubmed-article:8642802pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:8642802pubmed:meshHeadingpubmed-meshheading:8642802-...lld:pubmed
pubmed-article:8642802pubmed:meshHeadingpubmed-meshheading:8642802-...lld:pubmed
pubmed-article:8642802pubmed:meshHeadingpubmed-meshheading:8642802-...lld:pubmed
pubmed-article:8642802pubmed:meshHeadingpubmed-meshheading:8642802-...lld:pubmed
pubmed-article:8642802pubmed:meshHeadingpubmed-meshheading:8642802-...lld:pubmed
pubmed-article:8642802pubmed:meshHeadingpubmed-meshheading:8642802-...lld:pubmed
pubmed-article:8642802pubmed:meshHeadingpubmed-meshheading:8642802-...lld:pubmed
pubmed-article:8642802pubmed:meshHeadingpubmed-meshheading:8642802-...lld:pubmed
pubmed-article:8642802pubmed:meshHeadingpubmed-meshheading:8642802-...lld:pubmed
pubmed-article:8642802pubmed:meshHeadingpubmed-meshheading:8642802-...lld:pubmed
pubmed-article:8642802pubmed:meshHeadingpubmed-meshheading:8642802-...lld:pubmed
pubmed-article:8642802pubmed:meshHeadingpubmed-meshheading:8642802-...lld:pubmed
pubmed-article:8642802pubmed:meshHeadingpubmed-meshheading:8642802-...lld:pubmed
pubmed-article:8642802pubmed:year1995lld:pubmed
pubmed-article:8642802pubmed:articleTitleRilmenidine in patients with left ventricular hypertrophy: beyond the reduction of left ventricular mass.lld:pubmed
pubmed-article:8642802pubmed:affiliationDepartment of Internal Medicine, Federico II University, Naples, Italy.lld:pubmed
pubmed-article:8642802pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8642802pubmed:publicationTypeClinical Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8642802lld:pubmed